In fact, these biomarkers are currently under intense research; studies have shown that immunotherapy has clinical benefits for patients with high expression of PD-L1 and high tumor mutation burden, which are potential factors for identifying patients suitable for immunotherapy[19–21]; however, we still know too little about the predictive factors for the efficacy of immunotherapy combined with antiangiogenesis. This evidence concerns the gene CD274 and neoplasm.